Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has positive data suggesting two fixed-duration combinations containing its ...
BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced the selection of 10 abstracts for poster presentations and two abstracts for online publication at ...
BeiGene, Ltd. , a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced its new partnership with CLL Society, the world's leading authority for chronic ...